$90 Mil. Claritin Account Moves to Euro RSCG

NEW YORK Havas’ Euro RSCG has added Schering-Plough’s Claritin anti-allergy brand following a review, a client representative has confirmed. Work for the over-the-counter medication had been with WPP Group’s Ogilvy & Mather in New York.

Claritin spent $90 million on ads last year and more than $70 million through the first half of 2004, per Nielsen Monitor-Plus.

Euro RSCG has been a client roster shop since 1986 and already handles several Schering-Plough brands, including Coppertone, Correctal and Dr. Scholls.

The move could be the first of several shifts, as Schering-Plough has been talking to holding-company teams about its global professional-services marketing business, sources said [Adweek, June 21]. The client in Kenilworth, N.J., also markets Nasonex, Bain de Soleil and Dr. Scholls.

The Schering-Plough rep said she had no information about any other upcoming account switches.

The review includes communications directed at physicians and the healthcare community, currently handled by myriad agencies worldwide.

Holding companies contacted include WPP, Omnicom and Havas, sources said, all of which own agencies on the client’s roster. It is unclear whether Publicis, another holding company with Schering-Plough business, is also participating. (Publicis’ Zenith Media in New York handles Schering-Plough media duties, which are not in play.)

Schering-Plough spent about $300 million overall on U.S. ads in 2003, according to Nielsen Monitor-Plus. Sources estimated the overall business in play could be worth $400 million.